$10 Million
Convertible Note Offering
Dear Avvio Investor,
We are pleased to invite you to participate in Avvio Medical's current financing round through a convertible note offering targeting $10,000,000. This note bears an attractive 10% interest rate and provides a 15% discount on the per-share price for conversion to shares at the next round of financing.
Executive Summary
Avvio Medical stands at a pivotal point in its journey to revolutionize kidney stone treatment with our innovative Microsphere Cavitation System. We are seeking bridge financing to complete our pivotal clinical study for FDA clearance, which will then set the stage to begin commercializing our first-generation console and single-use procedure kit by the end of 2025.
Key shareholders, including Boston Scientific, our CEO, Chairman, and senior management team members, have committed to this round. Boston Scientific, which already holds a significant investment in our company, has received approval from its internal investment committee to participate at two times its pro rata, contingent upon existing investors' participation.
In-Person Town Hall Meeting
August 28 in San Francisco
Date
August 28, 5:30pm – 6:30pm
Location
2325 3rd Street, Suite 215
San Francisco, CA 94107
We invite you to come to our office next Wednesday. Along with a discussion of our technology and business plan, you will have the opportunity to see first-hand the recent progress that Avvio Medical has made and get a hands-on demonstration of the Avvio System. For those investors unable to attend in-person, we will hold a virtual town hall meeting online on August 29, from 7:30am - 8:30am, Pacific Time.
Please indicate your interest in the form at the bottom of this page.
Highlights of the Investment Opportunity
Technology Innovation
Avvio Medical’s Microsphere Cavitation System is poised to transform the kidney stone treatment market. Our system enables outpatient procedures without general anesthesia or fluoroscopy, offering a safe, cost-effective, and accessible alternative to current treatments.
Regulatory and Clinical Pathway
We have a clear path to FDA approval with our pivotal study beginning in September/October 2024. The FDA has endorsed our DeNovo pathway, and we anticipate market clearance by the end of 2025.
Market Potential
The kidney stone treatment market represents a $10 billion total global addressable market, driven by increasing incidence rates and a declining number of urologists. Our solution addresses these gaps, making kidney stone treatment more accessible and affordable.
Reimbursement Strategy
Our reimbursement path is robust, with validated strategies for new CPT III coding and a high-margin, single-use kit model. This ensures a strong financial foundation for market entry and growth.
Strategic Partnerships
We are engaged in ongoing dialogue with several major players in the medical device industry, including Boston Scientific, which underscores the strategic interest and potential exit opportunities post-FDA clearance.
Expression of Interest
Please fill out the form and we will reach out to you.
Full terms and conditions of the investment offering are described in the Note Purchase Agreement and Note documents, which we will send you upon your expression of interest.
This investment involves risk of loss of principal and is available to accredited investors only.
We look forward to your continued support as we advance toward making a significant impact in kidney stone treatment.
Best regards, Paul Molloy
